ERBB2 and breast cancer: The mammalian target of rapamycin (mTOR) inhibitor everolimus has been approved in combination with exemestane for treatment of hormone receptor-positive HER2-negative (HR + HER-) advanced breast cancer after failure of treatment with letrozole or anastrozole.